In Depth 24 Sep 2025 Eli Lilly’s strategy in motion: Beyond diabetes and obesity Delve into a biopharma giant’s strategy, Eli Lilly. This past year, the company secured regulatory milestones and strategic deals. September 24, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 26 Feb 2025 New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis? Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis. February 26, 2025 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2025 Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues. February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Feb 2024 Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A? Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition. February 27, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 8 Feb 2024 Could we see a new dawn for hair loss treatments? Discover the latest advances in hair loss treatments, from topical therapies to the the groundbreaking potential of JAK inhibitors. February 8, 2024 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
Opinion 1 Nov 2023 Could this be the start of a new era for PI3K drugs? There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […] November 1, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 28 Sep 2023 Obesity drug success sparks biotech buying spree The last few months have seen the obesity drug market soar, after new weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Ozempic took the world by storm with their incredible efficacy at inducing weight loss. These new drugs belong to a class of medications called GLP-1 analogs (or incretin-based therapies), which work by […] September 28, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2023 Hope for Alzheimer’s patients after Lilly drug results Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […] July 17, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2023 Lilly boosts obesity portfolio with Versanis Bio acquisition Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […] July 17, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2023 BioGeneration Ventures closes BGV Fund V at €150M BioGeneration Ventures (BGV), an early-stage venture capital company in European biopharma, has closed its BGV V fund at €150 million ($167.9 million), its largest fund since launching its first fund in 2006. BGV V was oversubscribed, with demand from both existing and new investors, with existing investors Eli Lilly and Company, Novo Holdings and Bristol […] July 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 FDA approves type 2 diabetes drug for children 10 and older The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company have announced. “As the burden of type 2 diabetes increases among young […] June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2023 Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline Eli Lilly and Company has announced positive results of the TRAILBLAZER-ALZ 2 phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease Rating Scale (iADRS). The primary endpoint of […] May 3, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email